Early 18F-FDG-PET/CT as a predictive marker for treatment response and survival in patients with metastatic colorectal cancer treated with irinotecan and cetuximab

Skougaard, Kristin; Nielsen, Dorte; Jensen, Benny Vittrup; Pfeiffer, Per; Hendel, Helle Westergren

doi:10.3109/0284186x.2016.1170197

Cited by 6 publications

(6 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although there are several studies that have evaluated the role of SUVmax as a predictive marker in such patients, only a few studies have examined the prognostic role of PET/ CT parameters in relation to overall survival and progression-free survival in patients with colorectal cancer (4,5). However, the results of studies investigating the role of PET/CT in the evaluation of treatments have revealed certain potential for Clinical Science the formation of a prognostic model that would include SUVmax along with classical prognostic markers (6,7).…”

Section: Introductionmentioning

confidence: 99%

The Prognostic Value of SUVmax of 18F-FDG PET/CT in Patients with Metastatic Colorectal Cancer

Sokolović¹,

Cerić

et al. 2020

ama

View full text Add to dashboard Cite

Objective. The aim of the study was to evaluate the prognostic value of the maximum standardized uptake value (SUVmax) of 18F-Fluorodeoxyglucose (18F-FDG) PET/CT in patients with metastatic colorectal cancer, and to compare it with classical prognostic markers.Materials and Methods. The study included 70 patients with metastatic colorectal cancer who had not been treated for the metastatic disease. The patients underwent 18F-FDG PET/CT as part of their routine diagnostic reevaluation. During the analysis, the value of the largest tumor diameter and SUVmax was determined for the lesion with the highest SUVmax observed. The values of CEA and CA 19-9 were recorded 7 days before the PET/CT analysis.Results. SUVmax and Carbohydrate antigen (CA)19-9 were found to be independent prognostic markers of disease progression within 12 months. Based on the Receiver Operating Characteristics (ROC) curve analysis, the patients could be divided into two groups: SUVmax≤4.1 vs. SUVmax>4.1. Patients with SUVmax values of 4.1 or less had significantly better progression-free survival within 12 months with an HR (95% CI) of 2.97 (1.4-6.3), relative to patients with SUVmax values above 4.1.Conclusion. SUVmax may be used as a novel prognostic marker of disease progression among patients with metastatic colorectal cancer. Values of SUVmax can be used to select patients with a more aggressive type of disease and higher risk for progression within 12 months of PET/CT analysis.

show abstract

Section: Introductionmentioning

confidence: 99%

The Prognostic Value of SUVmax of 18F-FDG PET/CT in Patients with Metastatic Colorectal Cancer

Sokolović¹,

Cerić

et al. 2020

ama

View full text Add to dashboard Cite

show abstract

“…In older series on mCRC patients, metabolic response correlated with objective response but not with survival. 8, 21, 22 So far, to our knowledge, no data on the effect of EGFR-blockade are available.…”

Section: Discussionmentioning

confidence: 99%

Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Colorectal cancer is the world's third most common malignancy and the second leading cause of cancer-related ORIGINAL ARTICLE Role of 18 4 Associate Professor & PMO 5 Medical Officer-NINMAS Correspondence Address: Dr. Papia Akhter, Assistant Professor, NINMAS, Block-D, BSMMU, Shahbag, Dhaka-1000…”

Section: Introductionmentioning

confidence: 99%

Role of F-18 FDG PET-CT in Follow up Patients with Rectal Carcinoma: Single Institute Based Study

Akhter,

Begum,

Siddique

et al. 2023

Bangladesh J. Nuclear Med.

View full text Add to dashboard Cite

Introduction: F-18 Fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET/CT) is a hybrid non-invasive imaging tool that integrates PET and CT into a single imaging device. It is used to detect and measure metabolic activity in a cancer cell and, hence, can provide anatomic and metabolic information. 18F-FDG PET/CT is useful for the detection of loco-regional recurrence, distant metastases, and monitoring therapy response in patients with rectal carcinoma. This study was done to see the usefulness of 18F-FDG PET/CT in the follow-up evaluation of patients with rectal carcinoma. Materials and Methods: This retrospective study was done in the PET/CT division of the National Institute of Nuclear Medicine & Allied Sciences (NINMAS) between January 2021 and December 2022. A total of 26 patients with rectal carcinoma, requested for an F-18 FDG PET-CT scan were enrolled in this study. Image findings were analyzed and properly documented in a predesigned format to evaluate the results. Results: Total 26 patients with an average age of 47.69 and a follow up period of 6 months to 5 years were enrolled in this study. Histologically adenocarcinoma was seen in 21 patients, four patients were mucinous, two were papillary, and carcinoid tumor was found in one patient. On PET/CT imaging, no metastases were found in 17 (65.4%) out of 26 patients and metastases was seen in 9 (34.6%) patients. Among them four (44.5%) had lung, two (22.2%) had lymph nodes, one (11.1%) had liver and lymph node metastases, one (%11.1) had skeletal metastases, and one (11.1%) had peritoneal metastases. No significant association was observed with histopathology or treatment protocol. CEA was higher in patients with metastases and lower in those without. Conclusion: 18F-FDG PET/CT is an effective tool in follow up patients with rectal carcinoma as it can accurately detect locoregional recurrence or distant metastases. Bangladesh J. Nuclear Med. 25(2): 105-109, 2022

show abstract

Early ¹⁸F-FDG-PET/CT as a predictive marker for treatment response and survival in patients with metastatic colorectal cancer treated with irinotecan and cetuximab

Cited by 6 publications

References 22 publications

The Prognostic Value of SUVmax of 18F-FDG PET/CT in Patients with Metastatic Colorectal Cancer

The Prognostic Value of SUVmax of 18F-FDG PET/CT in Patients with Metastatic Colorectal Cancer

Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial

Role of F-18 FDG PET-CT in Follow up Patients with Rectal Carcinoma: Single Institute Based Study

Contact Info

Product

Resources

About